Introduction {#s0005}
============

Case {#s0015}
----

A 60 year-old female was referred to Gynaecology clinic with abdominal distention and a palpable abdominal mass extending above the umbilicus. She was para two (normal deliveries), and post-menopausal for 10 years with no subsequent bleeding per vagina. She followed routine cervical screening smears, had never taken hormone replacement therapy (HRT), and was a non-smoker. She had no past medical history or family history of gynaecological or breast malignancy. Tumour markers were taken; CEA = 75.3 μg/L, CA199 = 81 kU/L, CA125 = 194 kU/L, and a CT abdomen and pelvis arranged querying bowel or ovarian primary given the raised tumour markers. Post-operative tumour markers included alpha feto-protein (AFP) = 11,677 kU/L and beta human chorionic gonadotrophin (hCG) = 8 mIU/L.

CT scan revealed a large midline mass (23 × 11.5 × 18.5 cm) predominantly cystic, with poorly defined walls, compressing and indistinguishable from the large bowel near the caecum and sigmoid colon, with bilateral hydronephrosis and hydroureter. The mass was deemed likely ovarian (bilateral) in origin with no significant lymphadenopathy, omental or extra-pelvic disease. However, given the raised CA199, CEA and the radiological appearances of a mass inseparable from the large bowel, the patient underwent US guided biopsy to confirm the site of origin. The biopsy was reported as poorly differentiated adenocarcinoma. Immunostains were positive for CDX2, CK20, CA125, and CK7 and negative for ER. Based on the clinical picture and immunostains the pelvic tumour was diagnosed as colonic in origin.

One month after initial imaging, the patient underwent attempted debulking surgery involving right hemi-colectomy, resection of the terminal ileum and caecum with ileostomy and mucus fistula formation. The tumour was densely adherent to the right anterior abdominal wall, mesentery of the small bowel, sigmoid colon, caecum and bladder. The proximal colon was dilated, indicating partial obstruction secondary to tumour, requiring a right hemicolectomy. Tumour was resected from the small bowel and the right anterior abdominal wall and bladder, being removed in piecemeal fragments.

Intra-operatively, superficial and deep hepatic nodules were palpable hence maximal debulking was not deemed appropriate given the extent of disease spread. The uterus, right or left ovary could not be separately identified from the tumour bulk, and the pelvis was inaccessible due to the large mass (20 cm size). Therefore the procedure was completed and further extra-colonic resection was not performed.

Pathology {#s0020}
---------

The pelvic tumour was extensively sampled and morphology showed a necrotic, heterogeneous tumour with solid, reticular and glandular pattern. There were goblet cells present in keeping with intestinal differentiation. The tumour showed Schiller Duval bodies, on the basis of which an AFP immunostain was performed, which was strongly and diffusely positive ([Fig. 1](#f0005){ref-type="fig"}). This confirmed the diagnosis of a yolk sac tumour. The tumour was positive for AE1/3, focally for CA125, CDX2, beta hCG, and very focally positive for CK7 and CK20. The tumour was negative for p53, WT1, CD10 and CD56. There was no endometrioid or serous carcinoma component present in the tumour. Compressed ovarian stroma was identified thereby confirming an ovarian origin ([Fig. 2](#f0010){ref-type="fig"}).

The right hemi-colectomy specimen showed tumour cells with a similar morphology to the pelvic tumour, which infiltrated into the mesenteric fat, mucosa of the ileum, base of the appendix and caecum. The overlying mucosa was intact. Lymph nodes showed no evidence of tumour metastases.

Based on morphology and immunohistochemistry, the final diagnosis was classified as primary ovarian yolk sac tumour (malignant germ cell tumour) with focal intestinal differentiation.

Outcome {#s0025}
-------

Post-surgical CT imaging 17 days post-operatively revealed pelvic recurrence, peritoneal thickening, liver metastases and small bowel obstruction. The disease was deemed rapidly progressive. A long line was inserted and total parental nutrition (TPN) commenced. Due to the presence of hepatic metastases, the patient was initially commenced on 2 cycles of EP chemotherapy (etoposide and cisplatin) before switching to POMB--ACE (POMB: methotrexate, vincristine, cisplatin, bleomycin; ACE: acinomycin, cyclophosphamide, etoposide) used for high risk germ cell tumours. EP induction allows chemotherapy to be delivered to patients who would otherwise develop major toxicity if they received full dose POMB first line. Following EP therapy, the patient had a marked clinical response and a dramatic reduction in AFP and beta hCG tumour markers. She remains under Oncology follow-up.

Discussion {#s0010}
==========

Ovarian germ cell tumours (OGCT) are rare, accounting for 2--5% of ovarian malignancies with an annual incidence of 1:100,000 and typically occur in young women (median age 19 years) ([@bb0005]). Yolk sac (endodermal sinus) tumours are highly malignant non-dysgerminomas and the second commonest (20--25%) subtype of ovarian germ cell tumours ([@bb0005], [@bb0010]). They characteristically present with a rapidly enlarging abdominal mass causing abdominal distention and pain, with raised AFP levels produced by the yolk sac cells. OGCTs are highly sensitive to combination chemotherapy, yet were historically associated with a poor prognosis and can prove fatal without prompt treatment. Most are unilateral and have subclinical metastases at presentation, with the tumour spreading locally throughout the peritoneum in preference to haematogenously. Survival rates of stages I--II yolk sac tumours are 60--100%, falling to 50--75% with stages II--IV disease. 40% yolk sac tumours display mixed histology with dysgerminoma subtypes (eg: teratoma) ([@bb0005]).

Germ cell tumours in post-menopausal patients are extremely rare, with very few case reports in the literature ([@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080], [@bb0085]), thereby explaining the initial diagnostic uncertainty in this case report regarding tumour type. Primary debulking surgery may not have been performed if pre-operative histology had revealed yolk sac characteristics.

To our knowledge, there are 20 published reports of ovarian endodermal yolk sac tumours in post-menopausal patients ranging between 53 and 86 years at presentation ([Table 1](#t0005){ref-type="table"}) ([@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050], [@bb0055], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080], [@bb0085]). Most ([@bb0060]) cases involved mixed yolk sac tumours with embryonal, endometrioid carcinoma, cystadenoma/cystadenofibroma or cystadenocarcinoma subtypes, the oldest case being 82 years of age ([@bb0010], [@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0055], [@bb0080], [@bb0085]). The remainder involved pure yolk sac tumour histology with the oldest reported patient being 86 years of age ([@bb0040], [@bb0045], [@bb0050], [@bb0060], [@bb0065], [@bb0070], [@bb0075], [@bb0080]). There is little knowledge concerning the development, treatment and outcome of post-menopausal yolk sac tumours. It is postulated that their pathogenesis differs from that in young adults, arising from a transformation or neometaplasia/retro-differentiation process from surface epithelial cells rather than from yolk cells alone ([@bb0055], [@bb0070], [@bb0080]). This theory is supported by isolated reports of these tumours originating from endometriotic deposits or endometrioid carcinomas ([@bb0010], [@bb0015], [@bb0020], [@bb0025]).

Endodermal yolk sac tumours are indeed rare in post-menopausal patients, but a rapidly enlarging pelvic--abdominal mass accompanied by raised AFP levels should alert clinicians and prompt appropriate management.
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![Yolk sac tumour 40 ×: AFP immunostain stain positive.](gr1){#f0005}

![Yolk sac tumour, 12.5 ×: Haematoxylin and eosin stain showing compressed ovarian stroma.](gr2){#f0010}

###### 

Summary of published case reports (1976--2012) regarding endometrial yolk sac tumours, including age at presentation, pathology and treatment.

  Number   Paper                         Age at presentation (years)   Histology                                                                                               Endometriosis   Treatment                                                                          Chemotherapy                                                                                                    Outcome
  -------- ----------------------------- ----------------------------- ------------------------------------------------------------------------------------------------------- --------------- ---------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- -----------------------------------------------
  1        Kammerer-Doak D et al. 1996   53                            Mixed: EST + embryonal carcinoma                                                                        No              TAH,BSO, omentectomy, appendicectomy, pelvic and para-aortic lymph node sampling   BEP --- bleomycin, etoposide, cisplatin (3 cycles)                                                              Disease free at 5 years
  2        Rutgers et al. 1986           50                            Mixed: EST + endometrioid carcinoma                                                                     Yes             TAH,BSO, omentectomy, peritoneal washings                                          5 cycles Vincristine/dactinomycin/cyclophosphamide pre-operatively and cisplatin/vinblastine post operatively   Deceased from disease (DOD)
  3        Nogales et al. 1996           64                            Mixed: EST + endometrioid carcinoma                                                                     No              TAH,BSO                                                                            Vincristine/dactinomycin/cyclophosphamide (3 cycles)                                                            Recurrence at 8 months, deceased at 14 months
  4        Nogales et al. 1996           71                            Mixed: EST + endometrioid carcinoma                                                                     Yes             TAH,BSO                                                                            Cisplatin based (6 cycles)                                                                                      Disease free at 12 months
  5        Nogales et al. 1996           71                            Mixed: EST + endometrioid carcinoma                                                                     No              TAH,BSO                                                                            Cisplatin based (1 cycle)                                                                                       DOD at 3 months
  6        Nogales et al. 1996           73                            Mixed: EST + carcinosarcoma                                                                             No              LSO, omentum, appendix and uterine biopsy                                          None                                                                                                            DOD at 5 months
  7        Horiuchi et al. 1998          53                            Mixed: EST + endometrioid carcinomal                                                                    No              TAH,BSO, omentectomy, pelvic lymph node biopsy                                     Vinblastine/pepleomycin/cisplatin/actinomycin D/cyclophosphamide (6 cycles)                                     DOD at 6 months
  8        Aria et al. 1999              71                            Mixed: mucinous cystadenocarcinoma-YST                                                                  No              TAH,BSO                                                                            Cisplatin and etoposide                                                                                         DOD at 6 months
  9        Mazur et al. 1988             82                            Mixed: mucinous cystadenofibroma-YST                                                                    No              TAH,BSO, omentectomy                                                               None                                                                                                            Disease free at 2 years
  10       Lopez et al. 2003             51                            Mixed: EC-YST, mucinous cystadenoma                                                                     Yes             TAH,BSO, omentectomy                                                               Cisplatin/etoposide/bleomycin (3 cycles)                                                                        DOD at 10 months
  11       Lange et al. 2012             86                            Pure: EST                                                                                               No              TAH,BSO, omentectomy, peritoneal stripping                                         BEP --- bleomycin, etoposide, cisplatin (4 cycles)                                                              Not documented
  12       Ferracini R et al. 1989       63                            Pure: EST                                                                                               No              TAH, partial removal of mass.                                                      None                                                                                                            DOD 2 days post operatively
  13       Brown J et al. 1976           57                            Pure: EST                                                                                               No              TAH,BSO, omentectomy                                                               None                                                                                                            DOD at 3 months
  14       Kinoshita K et al., 1990      62                            Pure: EST                                                                                               No              TAH,BSO, omentectomy                                                               Cisplatin, vinblastin, peplomycin (5 cycles)                                                                    Not documented
  15       Oh C et al. 2001              75                            Pure: EST                                                                                               No              TAH,BSO, sigmoid colectomy, omentectomy, pelvic lymph node biopsy                  Etopiside and cisplatin (3 cycles)                                                                              DOD at 4 months
  16       Pliskow S et al. 1993         54                            Pure: EST                                                                                               No              TAH,BSO, omentectomy                                                               Bleomysin, etoposide, cisplatin (3 cycles)                                                                      Disease free at 2 years
  17       Filiz G et al. 2003           76                            Pure: EST                                                                                               No              TAH, BSO, omentectomy, pelvic and para-aortic lymph node sampling                  Bleomycin, Etoposide and Cisplatin (4 cycles)                                                                   DOD at 6 months
  18       Meguro S et al. 2013          58                            Mixed: AFP producing adenocarcinoma with adenofibroma showing germ cell differentiation                 No              TAH,BSO, omentectomy                                                               Carboplatin and docetaxel (6 cycles)                                                                            Disease free at 12 months
  19       Roma A et al. 2014            61                            Mixed: papillary serous high grade carcinoma with minor components of endometrioid carcinoma and YST.   No              TAH,BSO and staging biopsies                                                       Intraperitoneal chemotherapy (6 cycles)                                                                         Persistent/recurrent disease at 6 months
  20       Roma A et al. 2015            70                            Pure: EST                                                                                               Yes             TAH,BSO and staging biopsies                                                       6 cycles                                                                                                        Recurrence at 7 months
